Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Intra-Cellular Therapies (ITCI) PT Raised to $90 at Jefferies
March 2, 2022 8:08 AM ESTJefferies analyst Andrew Tsai raised the price target on Intra-Cellular Therapies (NASDAQ: ITCI) to $90.00 (from $85.00) while maintaining a Buy rating.
The analyst commented, "Q4 Caplyta sales in mostly schizophrenia (SCZ) grew by +18% Q/Q to $25.5M (in line vs cons;... More
Intra-Cellular Therapies (ITCI) Misses Q4 EPS by 5c
March 1, 2022 7:34 AM ESTIntra-Cellular Therapies (NASDAQ: ITCI) reported Q4 EPS of ($1.05), $0.05 worse than the analyst estimate of ($1.00). Revenue for the quarter came in at $25.7 million versus the consensus estimate of $25.37 million.
For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.
... More